BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Walker RC, Brown TL, Jones-jackson LB, De Blanche L, Bartel T. Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias. J Nucl Med 2012;53:1091-101. [DOI: 10.2967/jnumed.111.098830] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Regelink JC, Minnema MC, Terpos E, Kamphuis MH, Raijmakers PG, Pieters-van den Bos IC, Heggelman BG, Nievelstein RJ, Otten RH, van Lammeren-Venema D, Zijlstra JM, Arens AI, de Rooy JW, Hoekstra OS, Raymakers R, Sonneveld P, Ostelo RW, Zweegman S. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol. 2013;162:50-61. [PMID: 23617231 DOI: 10.1111/bjh.12346] [Cited by in Crossref: 132] [Cited by in F6Publishing: 103] [Article Influence: 14.7] [Reference Citation Analysis]
2 Gómez León N, Aguado Bueno B, Herreros Pérez M, León Ramírez LF, Alegre A, Colletti PM, Rubello D, Carreras JL, Delgado Bolton RC. Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma. Clin Nucl Med 2021;46:310-22. [PMID: 33534256 DOI: 10.1097/RLU.0000000000003512] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dammacco F, Rubini G, Ferrari C, Vacca A, Racanelli V. 18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med 2015;15:1-18. [DOI: 10.1007/s10238-014-0308-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
4 Liang M, Su M, Wang R, Wang W, Fan C. Muscle Involvement of Multiple Myeloma Revealed by FDG PET/CT. Clinical Nuclear Medicine 2017;42:300-2. [DOI: 10.1097/rlu.0000000000001564] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Zamagni E, Nanni C, Tacchetti P, Pantani L, Marzocchi G, Zannetti B, Terragna C, Mancuso K, Rocchi S, Pezzi A, Testoni N, Fanti S, Cavo M. Positron Emission Tomography With Computed Tomography–Based Diagnosis of Massive Extramedullary Progression in a Patient With High-Risk Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 2014;14:e101-4. [DOI: 10.1016/j.clml.2013.12.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
6 Sherrod AM, Hari P, Mosse CA, Walker RC, Cornell RF. Minimal residual disease testing after stem cell transplantation for multiple myeloma. Bone Marrow Transplant 2016;51:2-12. [DOI: 10.1038/bmt.2015.164] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yang Q, Shen X, Su Z, Ju S. Emerging roles of noncoding RNAs in multiple myeloma: A review. J Cell Physiol 2019;234:7957-69. [PMID: 30370557 DOI: 10.1002/jcp.27547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Xu W, Li C, Zhao X, Lu J, Li L, Wu N, Zuo Y, Jing H, Dong Z, Zhang W, Zhang W. Whole-spine Computed Tomography Findings in SAPHO Syndrome. J Rheumatol 2017;44:648-54. [PMID: 28250144 DOI: 10.3899/jrheum.161075] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
9 Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2020;47:537-46. [PMID: 31776631 DOI: 10.1007/s00259-019-04605-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
10 Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, Nanni C, Geatti O, Isola M, Sperotto A, Buttignol S, Stocchi R, Corradini P, Cavo M, Fanin R. The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2015;21:1068-73. [DOI: 10.1016/j.bbmt.2015.03.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
11 Alessandrino F, DiPiro PJ, Jagannathan JP, Babina G, Krajewski KM, Ramaiya NH, Giardino AA. Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know. Insights Imaging 2019;10:25. [PMID: 30796644 DOI: 10.1186/s13244-019-0705-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Karunanithi S, Soundararajan R, Sharma P, Naswa N, Bal C, Kumar R. Spectrum of Physiologic and Pathologic Skeletal Muscle 18 F-FDG Uptake on PET/CT. American Journal of Roentgenology 2015;205:W141-9. [DOI: 10.2214/ajr.14.13457] [Cited by in Crossref: 19] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
13 Seval GC, Ozkan E, Beksac M. PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma. PET Clin 2019;14:369-81. [PMID: 31084776 DOI: 10.1016/j.cpet.2019.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Wang S, Xie Q, Lv W. Positron emission tomography/computed tomography imaging and rheumatoid arthritis. Int J Rheum Dis 2014;17:248-55. [DOI: 10.1111/1756-185x.12316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
15 Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood 2016;127:971-6. [DOI: 10.1182/blood-2015-07-635383] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 12.5] [Reference Citation Analysis]
16 Ko YH, Niedźwiecka K, Casal M, Pedersen PL, Ułaszewski S. 3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor André Goffeau. Yeast 2019;36:211-21. [PMID: 30462852 DOI: 10.1002/yea.3367] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
17 Todinova S, Krumova S, Radoeva R, Gartcheva L, Taneva SG. Calorimetric markers of Bence Jones and nonsecretory multiple myeloma serum proteome. Anal Chem 2014;86:12355-61. [PMID: 25478781 DOI: 10.1021/ac503677d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
18 Narquin S, Ingrand P, Azais I, Delwail V, Vialle R, Boucebci S, Tasu JP. Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma. Diagn Interv Imaging 2013;94:629-36. [PMID: 23683788 DOI: 10.1016/j.diii.2013.01.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
19 Usmani SZ, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N, Brown T, Bartel T, Anaissie E, van Rhee F. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121:1819-1823. [PMID: 23305732 DOI: 10.1182/blood-2012-08-451690] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 14.7] [Reference Citation Analysis]
20 Danner A, Brumpt E, Alilet M, Tio G, Omoumi P, Aubry S. Improved contrast for myeloma focal lesions with T2-weighted Dixon images compared to T1-weighted images. Diagn Interv Imaging 2019;100:513-9. [PMID: 31130374 DOI: 10.1016/j.diii.2019.05.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Lino AMM, Castelli JB, Szor RS, Fernandes F, Aiello VD. Diagnostic challenges in systemic amyloidosis: a case report with clinical and laboratorial pitfalls. Autops Case Rep 2021;11:e2021326. [PMID: 34631606 DOI: 10.4322/acr.2021.326] [Reference Citation Analysis]
22 Larbi A, Omoumi P, Pasoglou V, Michoux N, Triqueneaux P, Tombal B, Cyteval C, Lecouvet FE. Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI. Diagn Interv Imaging 2019;100:295-302. [PMID: 30704946 DOI: 10.1016/j.diii.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
23 Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013;122:4172-81. [PMID: 24144641 DOI: 10.1182/blood-2013-08-520890] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
24 Kothekar E, Raynor WY, Al-zaghal A, Jonnakuti VS, Werner TJ, Alavi A. Evolving Role of PET/CT-MRI in Assessing Muscle Disorders. PET Clinics 2019;14:71-9. [DOI: 10.1016/j.cpet.2018.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
25 Liu Y, Li K. Solitary plasmacytoma of maxillofacial bones: correlation of CT features with pathological findings. Dentomaxillofac Radiol 2020;49:20190277. [PMID: 31559843 DOI: 10.1259/dmfr.20190277] [Reference Citation Analysis]
26 Ak İ, Onner H, Akay OM. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT. Ann Hematol 2015;94:1567-75. [DOI: 10.1007/s00277-015-2410-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
27 Agarwal A, Chirindel A, Shah BA, Subramaniam RM. Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR Am J Roentgenol. 2013;200:884-890. [PMID: 23521465 DOI: 10.2214/ajr.12.9653] [Cited by in Crossref: 42] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
28 Xu F, Liu F, Pastakia B. Different Lesions Revealed by 18F-FDG PET/CT and 18F-NaF PET/CT in Patients With Multiple Myeloma. Clinical Nuclear Medicine 2014;39:e407-9. [DOI: 10.1097/rlu.0000000000000285] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Pan Q, Li J, Li F, Zhou D, Zhu Z. Characterizing POEMS Syndrome with 18 F-FDG PET/CT. J Nucl Med 2015;56:1334-7. [DOI: 10.2967/jnumed.115.160507] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
30 Gavriatopoulou M, Βoultadaki A, Koutoulidis V, Ntanasis-Stathopoulos I, Bourgioti C, Malandrakis P, Fotiou D, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Kastritis E, Terpos E, Dimopoulos MA, Moulopoulos LA. The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer J 2020;10:93. [PMID: 32978365 DOI: 10.1038/s41408-020-00360-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F. Interest of Pet Imaging in Multiple Myeloma. Front Med (Lausanne) 2019;6:69. [PMID: 31024917 DOI: 10.3389/fmed.2019.00069] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
32 Junxun L, Juan L, Xiuzhen T, Juan O, Bohuang Z, Junru L. Comparing Five Diagnostic Criteria for Multiple Myeloma: A Retrospective Study of 227 Cases. Tumori 2014;100:207-13. [DOI: 10.1177/030089161410000215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-strauss A. 18F-FDG Dynamic PET/CT in Patients with Multiple Myeloma: Patterns of Tracer Uptake and Correlation With Bone Marrow Plasma Cell Infiltration Rate. Clinical Nuclear Medicine 2015;40:e300-7. [DOI: 10.1097/rlu.0000000000000773] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
34 Bodet-Milin C, Eugène T, Bailly C, Lacombe M, Frampas E, Dupas B, Moreau P, Kraeber-Bodéré F. FDG-PET in the evaluation of myeloma in 2012. Diagn Interv Imaging 2013;94:184-9. [PMID: 23287424 DOI: 10.1016/j.diii.2012.12.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
35 Qiu Y, Jiang XY, Luo YP, Li J, Zhou DB, Cao XX. [A 55-year-old male with anemia and monoclonal gammopathy]. Zhonghua Xue Ye Xue Za Zhi 2019;40:783-5. [PMID: 31648486 DOI: 10.3760/cma.j.issn.0253-2727.2019.09.017] [Reference Citation Analysis]
36 Minarik J, Krhovska P, Hrbek J, Pika T, Bacovsky J, Herman M, Scudla V. Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016;160:305-9. [DOI: 10.5507/bp.2015.064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S. (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J 2013;3:e165. [PMID: 24292417 DOI: 10.1038/bcj.2013.61] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
38 Sachpekidis C, Goldschmidt H, Hose D, Pan L, Cheng C, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics. Eur J Nucl Med Mol Imaging 2014;41:1343-53. [PMID: 24562650 DOI: 10.1007/s00259-014-2721-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
39 Munshi NC, Anderson KC. Minimal residual disease in multiple myeloma. J Clin Oncol. 2013;31:2523-2526. [PMID: 23733782 DOI: 10.1200/jco.2013.49.2124] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
40 Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, Lai M, Pratt G; the British Society for Haematology Guidelines. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 2017;178:380-93. [DOI: 10.1111/bjh.14827] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 12.6] [Reference Citation Analysis]
41 Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-46. [PMID: 27511158 DOI: 10.1016/S1470-2045(16)30206-6] [Cited by in Crossref: 888] [Cited by in F6Publishing: 439] [Article Influence: 177.6] [Reference Citation Analysis]
42 Li X, Wu N, Zhang W, Liu Y, Ming Y. Differential diagnostic value of 18F-FDG PET/CT in osteolytic lesions. J Bone Oncol 2020;24:100302. [PMID: 32760643 DOI: 10.1016/j.jbo.2020.100302] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci 2017;18:E445. [PMID: 28218709 DOI: 10.3390/ijms18020445] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
44 Michaud-Robert AV, Jamet B, Bailly C, Carlier T, Moreau P, Touzeau C, Bourgeois M, Kraeber-Bodere F, Bodet-Milin C. FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients? Cancers (Basel) 2020;12:E1384. [PMID: 32481533 DOI: 10.3390/cancers12061384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Shi X, Yang Z, Wu L, Hu S, Jiang Q, Ba R, Zhuang Q, Yu X, Wang L, Xi X, Zhang Y, Zhu Y. Disseminated sclerotic bone lesions with normal (18)F-fluorodeoxyglucose uptake in polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome. Leuk Lymphoma 2015;56:2215-7. [PMID: 25453164 DOI: 10.3109/10428194.2014.987766] [Reference Citation Analysis]
46 Fonti R, Pace L, Cerchione C, Catalano L, Salvatore B, De Luca S, Pane F, Salvatore M, Del Vecchio S. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study. Clin Nucl Med 2015;40:303-8. [PMID: 25608167 DOI: 10.1097/RLU.0000000000000696] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
47 Abe Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K. Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma. Eur J Nucl Med Mol Imaging 2019;46:1325-33. [PMID: 30687892 DOI: 10.1007/s00259-019-4275-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Dutoit JC, Verstraete KL. Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Skeletal Radiol 2017;46:733-50. [PMID: 28289855 DOI: 10.1007/s00256-017-2609-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
49 Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol 2014;83:2203-23. [PMID: 25308249 DOI: 10.1016/j.ejrad.2014.09.012] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
50 Shi X, Hu S, Yu X, Zhuang Q, Luo M, Jiang Q, Wang L, Lu Y, Fei X, Xi X, Zhu Y. Clinicopathologic Analysis of POEMS Syndrome and Related Diseases. Clinical Lymphoma Myeloma and Leukemia 2015;15:e15-21. [DOI: 10.1016/j.clml.2014.04.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
51 Simeone FJ, Harvey JP, Yee AJ, O'Donnell EK, Raje NS, Torriani M, Bredella MA. Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states. Skeletal Radiol 2019;48:773-9. [PMID: 30218303 DOI: 10.1007/s00256-018-3066-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
52 Peller PJ. Multiple myeloma. PET Clin 2015;10:227-41. [PMID: 25829088 DOI: 10.1016/j.cpet.2014.12.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
53 Okasaki M, Kubota K, Minamimoto R, Miyata Y, Morooka M, Ito K, Ishiwata K, Toyohara J, Inoue T, Hirai R. Comparison of (11)C-4’-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma. Ann Nucl Med. 2015;29:224-232. [PMID: 25421383 DOI: 10.1007/s12149-014-0931-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
54 Biran N, Ely S, Chari A. Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques. Curr Hematol Malig Rep 2014;9:368-78. [DOI: 10.1007/s11899-014-0237-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
55 Nakamoto Y, Kurihara K, Nishizawa M, Yamashita K, Nakatani K, Kondo T, Takaori-Kondo A, Togashi K. Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2013;40:708-15. [PMID: 23340595 DOI: 10.1007/s00259-012-2333-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]